Description

Perrigo Company’s $600 Million Portfolio Reset — Can It Finally Unlock The Turnaround?

The latest financial results and accompanying commentary from Perrigo Company plc illustrate a business undergoing a strategic transition amidst a mixed operating environment. Perrigo maintains a leading position in the U.S. store brand over-the-counter (OTC) market and strong branded OTC franchises in Europe, with approximately equal revenue contributions from these two segments, though geographically distinct. The company’s performance in the second quarter of 2026 reflected ongoing challenges in category softness, particularly in seasonal self-care categories such as cough, cold, allergy, and summer-related products. These factors, combined with retailer inventory destocking, resulted in a 3.1% decline in core net sales year-over-year and a 3.2% drop on an all-in basis, though improvements in category trends were noted as the quarter progressed. Perrigo’s leadership highlighted their strategic “Three-S” plan—Stabilize, Streamline, and Strengthen—which has driven operational improvements such as enhanced service levels (U.S.